Pallante Pierlorenzo, Pisapia Pasquale, Bellevicine Claudio, Malapelle Umberto, Troncone Giancarlo
Institute of Experimental Endocrinology and Oncology (IEOS) "G. Salvatore," National Research Council (CNR), Naples, Italy.
Department of Public Health, University of Naples Federico II, Naples, Italy.
Acta Cytol. 2019;63(3):171-181. doi: 10.1159/000496213. Epub 2019 Feb 13.
Molecular cytopathology is a rapidly evolving field of cytopathology that provides biological information about the response to personalised therapy and about the prognosis of neoplasms diagnosed on cytological samples. Biomarkers such as circulating tumour cells and circulating tumour DNA are increasingly being evaluated in blood and in other body fluids. Such liquid biopsies are non-invasive, repeatable, and feasible also in patients with severe comorbidities. However, liquid biopsy may be challenging due to a low concentration of biomarkers. In such cases, biomarkers can be detected with highly sensitive molecular techniques, which in turn should be validated and integrated in a complex algorithm that includes tissue-based molecular assessments. The aim of this review is to provide the cytopathologist with practical information that is relevant to daily practice, particularly regarding the emerging role of circulating tumour cells in the field of predictive molecular pathology.
分子细胞病理学是细胞病理学中一个快速发展的领域,它提供有关对个性化治疗的反应以及经细胞学样本诊断的肿瘤预后的生物学信息。诸如循环肿瘤细胞和循环肿瘤DNA等生物标志物越来越多地在血液和其他体液中得到评估。这种液体活检是非侵入性的、可重复的,并且对于患有严重合并症的患者也是可行的。然而,由于生物标志物浓度较低,液体活检可能具有挑战性。在这种情况下,可以使用高度灵敏的分子技术检测生物标志物,而这些技术反过来又应在包括基于组织的分子评估的复杂算法中得到验证和整合。本综述的目的是为细胞病理学家提供与日常实践相关的实用信息,特别是关于循环肿瘤细胞在预测性分子病理学领域的新兴作用。